Search - tctmd.com

Displaying 401 - 420 of 2294

Sort: Relevancy | Date

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

Todd Neale

October 04, 2022

News Conference News TCT 2022

Pascal TEER Device Performs Well in Patients With Complex Anatomy

Yael L. Maxwell

September 26, 2022

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

L.A. McKeown

September 23, 2022

News Conference News TCT 2022

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

Yael L. Maxwell

September 23, 2022

Presentation TCT 2022

State-of-the-Art Lecture: Future Device Therapies in PE

Presenter: Robert Lookstein

September 19, 2022

Presentation TCT 2022

Intermediate-Risk PE Case (NewYork-Presbyterian/Columbia University Irving Medical Center): Case Conclusion

Presenter: Sanjum Sethi

September 19, 2022

Presentation TCT 2022

What Do the Clinical Trials Tell Us to Do in Intermediate-Risk PE?

Presenter: Eric Secemsky

September 19, 2022

Presentation TCT 2022

Large Bore Thrombectomy: Are We Any Closer to Understanding Which Device Is Best?

Presenter: Catalin Toma

September 19, 2022

Presentation TCT 2022

CDT: New Devices, Drugs, and Duration?

Presenter: Andrew Sharp

September 19, 2022

Presentation TCT 2022

Intermediate-Risk PE Case (NewYork-Presbyterian/Columbia University Irving Medical Center): Case Intro

Presenter: Sanjum Sethi

September 19, 2022

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Todd Neale

September 18, 2022

News Conference News TCT 2022

Pulmonary Artery Denervation in Idiopathic PAH Ups 6-Minute Walk Test

Shelley Wood

September 18, 2022

Presentation TCT 2022

Reducer Device Overview and Mechanism of Action

Presenter: Allen Jeremias

September 18, 2022

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

Todd Neale

September 18, 2022

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

Presentation TCT 2022

Future Vision: Clinical and Technology Requirements for the Successful Development of Transcatheter Tricuspid Therapy Programs

Presenter: Azeem Latib

September 17, 2022

Presentation TCT 2022

Clinical Benchmarks for Therapy Success in Transcatheter Tricuspid Therapy

Presenter: David Cohen

September 17, 2022

Presentation TCT 2022

Physiologic and Hemodynamic Parameters Influencing Device Selection and Clinical Outcomes

Presenter: Neil Fam

September 17, 2022

Presentation TCT 2022

To Repair or Replace: A Treatment Algorithm Derived from Multimodality Imaging

Presenter: Rebecca Hahn

September 17, 2022

Advertisement

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

Pascal TEER Device Performs Well in Patients With Complex Anatomy

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

State-of-the-Art Lecture: Future Device Therapies in PE

Intermediate-Risk PE Case (NewYork-Presbyterian/Columbia University Irving Medical Center): Case Conclusion

What Do the Clinical Trials Tell Us to Do in Intermediate-Risk PE?

Large Bore Thrombectomy: Are We Any Closer to Understanding Which Device Is Best?

CDT: New Devices, Drugs, and Duration?

Intermediate-Risk PE Case (NewYork-Presbyterian/Columbia University Irving Medical Center): Case Intro

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Pulmonary Artery Denervation in Idiopathic PAH Ups 6-Minute Walk Test

Reducer Device Overview and Mechanism of Action

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Future Vision: Clinical and Technology Requirements for the Successful Development of Transcatheter Tricuspid Therapy Programs

Clinical Benchmarks for Therapy Success in Transcatheter Tricuspid Therapy

Physiologic and Hemodynamic Parameters Influencing Device Selection and Clinical Outcomes

To Repair or Replace: A Treatment Algorithm Derived from Multimodality Imaging

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content